{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "a55ef56f7bdaa235d46e61bbd501b58c",
    "title": "Nemluvio WeeklyTracker: TRx up \\(+1\\%\\) WoW, NRx down \\(-3\\%\\) WoW; insider transaction less of a concern",
    "source_uri": "2025-08-29/Galderma Nemluvio Weekly Tracker TRx up 1 WoW NRx down -3 WoW insider transaction less of a concern Galderma Nemluvio We_2025-08-29",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-26T23:14:20.650743",
      "extracted_at": "2025-10-26T23:14:20.650748"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 10,
        "successful_pages": 10,
        "date": "2025-08-29",
        "publication": "2025-08-29",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 9,
          "removed_paragraphs": 33,
          "reduction_ratio": 0.5750382414594074
        },
        "input_relative_path": "2025-08-29"
      }
    }
  },
  "passages": [
    {
      "passage_id": "48a88ebbe4ddf59a",
      "text": "We provide our weekly tracker for Nemluvio Rx in the US up to 22 August: Nemluvio changed \\(+1\\% / - 3\\%\\) WoW in TRx/NRx WoW (vs. \\(+7\\% / + 6\\%\\) for Ebglvss). \\(+4\\% / + 2\\%\\) increased in TRx/NRx on a 4- week rolling basis. The insider sale (CHF16.8mn yesterday) YTD only represents a small portion of long- held shares.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "56fbd99db2c4c332",
      "text": "We update our weekly US TRx/NRx data for Nemluvio to the week ending 22 August. Based on the latest IQVIA data Nemluvio US TRx increased by \\(+1\\%\\) to 2,765, vs. 2,738 in the week ending 15 August, while NRx decreased by \\(- 3\\%\\) to 1,095 vs. 1,129 in the prior week; we note NRx increased by \\(+8\\%\\) in the week ending 15 August. On a 4- week rolling basis, both TRx and NRx for Nemluvio TRx was \\(+4\\% / + 2\\%\\) WoW. For comparison, Nemluvio's key competitor Ebglvss had a good week, with \\(+7\\% / + 6\\%\\) TRx/NRx to 2,234/1,009 (vs. 2,096/953 in the week ending 15 August). We note GALD emphasized that IQVIA only captures the paid script for Nemluvio (as GALD uses a special channel for free drugs), while IQVIA captures both free and paid scripts for LLY's Ebglvss (as LLY reimburses the channel partner after). Following the resumption of Symphony data from Bloomberg, we also include this TRx/NRx data for completeness. See Figs 1- 5 for details. Additionally, we included 2Q25 Nemluvio switching data in Figs 6- 11 (detailed analysis see: Galderma: Nemluvio Weekly Tracker: Special Edition with favorable 2Q25 switching data (18/07/25)).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "92d0564d930d5974",
      "text": "It has been a relatively quiet week for GALD, with shares continuing to perform well at \\(+3\\%\\) this week (vs. \\(- 1\\%\\) for SXDE).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "b00a8724df0e2b03",
      "text": "- Insider transaction: We note there was an insider transaction this week, where CHF16.8mn of shares sold by an executive member on the Board/ Member of senior management on August 26th (see link). We caught up with the company: GALD confirmed that the transaction is by a member of the management team, but no further information on the individual executive can be disclosed in Switzerland. The company noted the transactions year to date represent a small portion ( \\(\\sim 20\\%\\) ) of the total holdings by the management team",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "da4e7f6310e73a39",
      "text": "This research report has been prepared in whole or in part by equity research analysts based outside the US who are not registered/qualified as research analysts with FINRA.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "2ae07b557a7f7eca",
      "text": "Please see analyst certifications and important disclosures beginning on page 5. Completed: 29- Aug- 25, 11:12 GMT Released: 29- Aug- 25, 11:17 GMT Restricted - External",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "49513b1b707c61f0",
      "text": "European Pharmaceuticals & Life Sciences",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "6b1e0b01a2bfd0b0",
      "text": "Price (28- Aug- 25) Potential Upside/Downside +0.1% Source: Bloomberg, Barclays Research",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "28b46f151d8765cf",
      "text": "and board members, and the management and Board remain significant shareholders and large part of some of GALD's executives' personal wealth continues to be held in Galderma shares. The large majority of the management team's shareholdings are a result of executives' personal investments in Galderma alongside the private equity consortium in 2019 or upon joining Galderma, which had been inaccessible to those executives until recently.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "4e93fe617707b789",
      "text": "- Nemo competitor: Sanofi's amlitelimab (every 4 weeks, Q4W, and every 12 weeks, Q12W) P3 COAST 1 topline readout at 24 weeks in AD will come any day now (COAST 1, NCT06130566, primary completion 23/07/2025), followed by P3 SHORE data in 2H25 (NCT06224348, primary completion 21/08/2025). We are constructive on amlitelimab Q4W to generate a competitive profile vs. Dupixent (less convinced in Q12W, see preview: Sanofi: Amlitelimab preview: The next big test in the battle for AD leadership (26/08/25)), but view it as less of a competitive concern for Nemluvio (see detailed discussions: Galderma: Thoughts on upcoming competitor amlitelimab P3 AD data + Nemluvio Weekly Tracker: TRx up +10% WoW, NRx up +8% WoW (22/08/25)).",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "5af8a1d5f6027eae",
      "text": "Overall, we continue to be bullish on atopic dermatitis (AD) opportunity and see it as a large and growing market, with low penetration - only \\(\\sim 15 - 16\\%\\) of biological eligible AD patients are currently treated as indicated by Sanofi (see: Galderma: AbbVie/Sanofi 2Q25 read- through to Nemluvio and Injectable Aesthetics (01/08/25)). Overall, despite the relatively less competitive EAS175 data for Nemluvio vs. peers, we continue to be positive on Nemluvio given 1) its differentiated clinical profile with rapid and significant relief from itch (onset of action as early as week 1 vs. week 4 for Ebglyss), well- tolerated safety profile, and the 4QW dosing schedule (Q8W for maintenance in atopic dermatitis, AD) vs. Q2W for Dupixent/Ebglyss (Ebglyss has Q4W maintenance); 2) large market potential for atopic dermatitis (AD), with multiple biologic entrants further helping to expand the AD market current biologic penetration rate at mid- teens; and 3) strong initial launch indicating the good execution from GALD. We reiterate our OW rating for GALD.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "a641c21a2bd456b4",
      "text": "FIGURE 1. Nemluvio and Ebglyss TRx from IQVIA - Weekly",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "8a736458cb8f7730",
      "text": "FIGURE 2. Nemluvio and Ebglyss NRx from IQVIA - Weekly",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "b3e1b60020953943",
      "text": "Source: Barclays Research, RAPID Weekly Audit, Aug 2024 - Aug 2025 Copyright IQVIA. All rights reserved",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "562879f408d6df4e",
      "text": "FIGURE 3. Nemluvio TRx vs. peers reset to launch, per Symphony data",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "50b4cb6401661dc2",
      "text": "FIGURE 4. Nemluvio NRx vs. peers reset to launch, per Symphony data",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "b6f0a47ac627a432",
      "text": "Source: Barclays Research, Symphony data",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "5b078644b3ef9362",
      "text": "Source: Barclays Research, Symphony data",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "38745b196e0f3db7",
      "text": "FIGURE 5. Nemluvio showed strong launch vs. peers, per Symphony data- Weekly",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "91b3828cbefe3bfb",
      "text": "Source: Barclays Research, Symphony data",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "18490697976d17d9",
      "text": "FIGURE 6. NTBx: Key Immunology products",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "aa7f50ae25478951",
      "text": "Source: Barclays Research, National Prescription Audit, Apr 2018 - Jun 2025, Copyright IQVIA. All rights reserved",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "bb07c80859627d98",
      "text": "FIGURE 7. Patient % switching from Dupixent in Q25",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "89ab339c16112198",
      "text": "FIGURE 8. Patient % switching from Dupixent in 2Q25",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "fbd2c979f446a0aa",
      "text": "Source: Barclays Research, National Prescription Audit, Jan 2025 - Jun 2025, Copyright IQVIA. All rights reserved",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "0ce5630fa478ec22",
      "text": "FIGURE 9. Nemluvio looks to have lower switch-out % in 2Q25, closer to Ebglyss",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "729ee779510dc620",
      "text": "Aug 24Sep 24Oct 24Nov 24Dec 24Jan-25Feb-25Mar-25Apr-25May-25Jun-25NEMLUVIOTOTAL Rx (TRx)42738691,1671,8842,2673,1144,6096,0557,0128,831NEW Rx (NRx)42597367811,0131,2031,6972,5052,9933,2944,020Switch in1651661862012683625548309221097Switch in / TRx (%)25%24%19%16%11%12%12%12%14%13%12%Switch out42333898989121169180197236Switch out / TRx (%)1%3%3%5%4%4%4%4%3%3%3%EBGLYSSSwitch in / Switch out Ratio16.37.25.62.33.03.03.34.64.74.6TOTAL Rx (TRx)1326841,6652,4053,0184,2035,4575,9887,697NEW Rx (NRx)1316261,3181,4961,7442,4292,9612,9863,780Switch in67227404422503628660640849Switch in / TRx (%)51%33%24%18%17%15%12%11%11%Switch out61722466095126136Switch out / TRx (%)1%1%1%2%1%2%2%2%Switch in / Switch out Ratio37.823.819.210.910.56.95.16.2",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "c34ff0f07547ceee",
      "text": "Source: Barclays Research, National Prescription Audit, Aug 2024 - Jun 2025, Copyright IQVIA. All rights reserved",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "a182559479479c39",
      "text": "FIGURE 10. Switches to Nemluvio from",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "da792a4103a2a011",
      "text": "FIGURE 11. Switches from Nemluvio to",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "13d74aa0a0aee23d",
      "text": "Source: Barclays Research, National Prescription Audit, Aug 2025 - Jun 2025, Copyright IQVIA. All rights reserved",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "1eaa908e0e4a06fb",
      "text": "Source: Barclays Research, National Prescription Audit, Aug 2025 - Jun 2025, Copyright IQVIA. All rights reserved",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "e814ba54554fa438",
      "text": "I, Yihan Li, PhD, hereby certify (1) that the views expressed in this research report accurately reflect my personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of my compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "0a059d4336006ab7",
      "text": "Galderma (GALD.S, 28- Aug- 2025, CHF 139.80), Overweight/Neutral, J",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "2773e4d36b578620",
      "text": "Unless otherwise indicated, prices are sourced from Bloomberg and reflect the closing price in the relevant trading market, which may not be the last available closing price at the time of publication.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "93604dad68d4ab0c",
      "text": "P: A partner, director or officer of Barclays Capital Canada Inc. has, during the preceding 12 months, provided services to the subject company for remuneration, other than normal course investment advisory or trade execution services.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "a910c33bde094d42",
      "text": "R: Barclays Capital Canada Inc. has received compensation for investment banking services from this issuer in the past 12 months.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "0e275083aea6055d",
      "text": "S: This issuer is a Corporate Broker to Barclays PLC.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "5dfc5f32ebc3195f",
      "text": "U: The equity securities of this Canadian issuer include subordinate voting restricted shares.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "fb25d232f394775c",
      "text": "V: The equity securities of this Canadian issuer include non- voting restricted shares.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "2e32777bf10b7644",
      "text": "The enclosed materials include information derived from market research information provided by IQVIA, Inc. and its affiliated companies (\"IQVIA\"). IQVIA market research information is proprietary to IQVIA and available on a confidential basis by subscription from IQVIA. IQVIA market research information reflects estimates of marketplace activity and should be treated accordingly. The statements, findings, conclusions, views, and opinions contained and expressed herein are not necessarily those of IQVIA Inc. or any of its affiliated or subsidiary entities. Any analysis is independently arrived at by Barclays, on the basis of information from various sources.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "cdad8a278275878b",
      "text": "Overweight - The stock is expected to outperform the unweighted expected total return of the industry coverage universe over a 12- month investment horizon.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "7fa301c3029526f0",
      "text": "Equal Weight - The stock is expected to perform in line with the unweighted expected total return of the industry coverage universe over a 12- month investment horizon.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "56ef8131a2e76f3a",
      "text": "Underweight - The stock is expected to underperform the unweighted expected total return of the industry coverage universe over a 12- month investment horizon.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "25451f7b7bc3d67a",
      "text": "Positive - industry coverage universe fundamentals/valuations are improving.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "f66b20ba8dff99d0",
      "text": "Neutral - industry coverage universe fundamentals/valuations are steady, neither improving nor deteriorating.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "9acbccfbdab5653a",
      "text": "Negative - industry coverage universe fundamentals/valuations are deteriorating.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "1e82ad3a9365eb44",
      "text": "Below is the list of companies that constitute the \"industry coverage universe\":",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "1102b4657f4bacde",
      "text": "European Pharmaceuticals & Life Sciences argenx (ARGX.BR)",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "db0d85d5f41e53e5",
      "text": "Genmab A/S (GMAB.CO)",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "96428221e59f265a",
      "text": "H Lundbeck A/S (HLUNb.CO)",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "8c8311a675830ab2",
      "text": "Lonza Group AG (LONN.S)",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "9aa5a7de81783aba",
      "text": "Novo Nordisk (NOVOb.CO)",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "b7d388029242ebed",
      "text": "Sartorius AG (SATG_p.DE)",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "16d9f740dbb33cd7",
      "text": "Grifols SA (GRLS.MC)",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "05cd1bcd0d1cd310",
      "text": "Hikma Pharmaceuticals PLC (HIK.L)",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "9e5fba77cae883bd",
      "text": "Merck KGaA (MRCG.DE)",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "10c0a63d7d885052",
      "text": "Polypeptide Group AG (PPGN.S)",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "42b06d7fe0ca5475",
      "text": "Sartorius Stedim Biotech (STDM.PA)",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "2f99bdff87fbde9b",
      "text": "Zealand Pharma A/S (ZELA.CO)",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "0069bbb0165c3ef3",
      "text": "Swedish Orphan Biovitrum (SOBIV.ST)",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "0efb48abb9a30eb4",
      "text": "In addition to any ratings assigned under Barclays' formal rating systems, this publication may contain investment recommendations in the form of trade ideas, thematic screens, scorecards or portfolio recommendations that have been produced by analysts within Equity Research. Any such investment recommendations shall remain open until they are subsequently amended, rebalanced or closed in a future research report.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "2925e974075643d3",
      "text": "Barclays may also re-distribute equity research reports produced by third-party research providers that contain recommendations that differ from and/or conflict with those published by Barclays' Equity Research Department.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "13a377a1631b10db",
      "text": "Barclays Equity Research may have published other investment recommendations in respect of the same securities/instruments recommended in this research report during the preceding 12 months. To view all investment recommendations published by Barclays Equity Research in the preceding 12 months please refer to https://live.barcap.com/go/research/Recommendations.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "547e739e15c08a85",
      "text": "Stock Rating: OVERWEIGHTIndustry View: NEUTRALClosing Price: CHF 139.80 (28-Aug-2025)",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "0b262d2772444820",
      "text": "Rating and Price Target Chart - CHF (as of 28-Aug-2025)Currency=CHF",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "ab7a8b03ae0eb026",
      "text": "Source: IDC, Barclays Research",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "7337b2da8f54b220",
      "text": "Link to Barclays Live for interactive charting",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "02329cd2a47d8f2e",
      "text": "Publication DateClosing Price*RatingAdjusted Price Target25-Jul-2025133.50140.0007-Jul-2025117.30Overweight133.00",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "fa8afb1aebada437",
      "text": "Source: Bloomberg, Barclays Research",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "dc1a986fe9301270",
      "text": "\\*This is the closing price referenced in the publication, which may not be the last available closing price at the time of publication.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "92daf49801c79e28",
      "text": "Historical stock prices and price targets may have been adjusted for stock splits and dividends.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "579d0cba996189d4",
      "text": "Valuation Methodology: We value GALD using both a relative valuation methodology (both EV/EBITDA and P/E) and NPV analysis to arrive at our price target. we arrive at a valuation of CHF \\(\\sim 33bn\\) implying CHF140/sh. for GALD by calculating a WACC of \\(7.1\\%\\) and assume a terminal growth rate of \\(2.2\\%\\) . On relative valuation our CHF140/sh valuation implies a \\(\\sim 15\\% / \\sim 3\\%\\) premium (EV/EBITDA) and \\(\\sim 28\\% / \\sim 11\\%\\) premium (P/E) to self- care/ consumer peer average in 2027/28E which we think is reasonable given GALD's higher growth prospects.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "1e02071430eff080",
      "text": "Risks which May Impede the Achievement of the Barclays Research Valuation and Price Target: Nemluvio (Atopic Dermatitis) - Uptake Challenges Despite a strong initial launch, Nemluvio faces headwinds that may hinder its growth trajectory. Competitive pressures, reimbursement hurdles, and prescriber hesitancy are contributing to slower-than- expected adoption. Notably, KOL feedback suggests limited penetration into biologic- naive AD patients, which could restrict market expansion. Additionally, if discontinuation rates remain high, Nemluvio may struggle to maintain launch momentum. Relfyess (QM- 1114) - Regulatory Uncertainty Relfyess received a Complete Response Letter (CRL) from the FDA due to Chemistry, Manufacturing, and Controls (CMC) deficiencies. GALD plans to refile in the US by late 2025, but any delays or setbacks in the approval process could impact launch timelines and market penetration, posing a risk to revenue forecasts. US Injectable Aesthetics - Macro Headwinds The injectable aesthetics segment is vulnerable to macroeconomic pressures in the US. A greater- than- anticipated slowdown in consumer spending on elective procedures could dampen demand, affecting growth momentum and profitability in this discretionary category. Dermatological Skincare - Intensifying Competition GALD faces rising competition in dermatological skincare from both established players and new entrants. Brands like L'Oreal's CeraVe are aggressively expanding, threatening GALD's market share in key lines such as Cetaphil. This competitive pressure could lead to revenue erosion if GALD fails to differentiate or defend its positioning. Tariffs & Geopolitical Risks - Margin Pressure Geopolitical uncertainties and potential tariff escalations—such as the proposed \\(50\\%\\) US- EU tariff with a July 9 deadline—could increase operational costs and disrupt supply chains. While currently manageable, any worsening of trade conditions may exert pressure on margins and profitability.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "82a4a04c7a1197ca",
      "text": "This material is distributed in Canada by Barclays Capital Canada Inc., a registered investment dealer, a Dealer Member of Canadian Investment Regulatory Organization (www.ciro.ca), and a Member of the Canadian Investor Protection Fund (CIPF).",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "2c7fdbb2705770ad",
      "text": "This communication is directed at persons who are a \"Wholesale Client\" as defined by the Australian Corporations Act 2001.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "06b8f579dda4d771",
      "text": "Middle East: Nothing herein should be considered investment advice as defined in the Israeli Regulation of Investment Advisory, Investment Marketing and Portfolio Management Law, 1995 (\"Advisory Law\"). This document is being made to eligible clients (as defined under the Advisory Law) only. Barclays Israeli branch previously held an investment marketing license with the Israel Securities Authority but it cancelled such license on 30/11/2014 as it solely provides its services to eligible clients pursuant to available exemptions under the Advisory Law, therefore a license with the Israel Securities Authority is not required. Accordingly, Barclays does not maintain an insurance coverage pursuant to the Advisory Law.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "796499deac73a6fe",
      "text": "Russia: This material is not intended for investors who are not Qualified Investors according to the laws of the Russian Federation as it might contain information about or description of the features of financial instruments not admitted for public offering and/or circulation in the Russian Federation and thus not eligible for non- Qualified Investors. If you are not a Qualified Investor according to the laws of the Russian Federation, please dispose of any copy of this material in your possession.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "7be7b1052f987a05",
      "text": "Sustainable Investing Related Research: There is currently no globally accepted framework or definition (legal, regulatory or otherwise) of, nor market consensus as to what constitutes a 'sustainable', 'ESG', 'green', 'climate- friendly' or an equivalent company, investment, strategy or consideration or what precise attributes are required to be eligible to be categorised by such terms. This means there are different ways to evaluate a company or an investment and so different values may be placed on certain sustainability credentials as well as adverse ESG- related impacts of companies and ESG controversies. The evolving nature of sustainable investing considerations, models and methodologies means it can be challenging to definitively and universally classify a company or investment under a sustainable investing label and there may be areas where such companies and investments could improve or where adverse ESG- related impacts or ESG controversies exist. The evolving nature of sustainable finance related regulations and the development of jurisdiction- specific regulatory criteria also means that there is likely to be a degree of divergence as to the interpretation of such terms in the market. We expect industry guidance, market practice, and regulations in this field to continue to evolve.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "3a2542c54d735cd0",
      "text": "Any information, data, image, or other content including from a third party source contained, referred to herein or used for whatsoever purpose by Barclays or a third party (\"Information\"), in relation to any actual or potential 'ESG', 'sustainable' or equivalent objective, issue, factor or consideration is not intended to be relied upon for ESG or sustainability classification, regulatory regime or industry initiative purposes (\"ESG Regimes\"), unless otherwise stated. Nothing in these materials, including any images included therein, is intended to convey, suggest or indicate that Barclays considers or represents any product, service, person or body mentioned in these materials as meeting or qualifying for any ESG or sustainability classification, label or similar standards that may exist under ESG Regimes. Barclays has not conducted any assessment of compliance with ESG Regimes. Parties are reminded to make their own assessments for these purposes.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "14b0f2446080c103",
      "text": "IRS Circular 230 Prepared Materials Disclaimer: Barclays does not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannot be used, by you for the purpose of avoiding U.S. tax- related penalties; and (ii) was written to support the promotion or marketing of the transactions or other matters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.",
      "page": 10,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "8ecf5f701f73bde6",
      "name": "Adjusted Price",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d1cf412485ca8530",
      "name": "Advisory Law",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d2b87e3914bc2def",
      "name": "Atopic Dermatitis",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "facedae141187a9f",
      "name": "Australian Corporations",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "46a2e39eafb9f3ae",
      "name": "Barclays Capital",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "64387d09d2494c79",
      "name": "Barclays Capital Canada Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4d2d57430a6b5e51",
      "name": "Barclays Equity",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d1d3bfaf58595d0a",
      "name": "Barclays Israeli",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "05ab2ec667d770bf",
      "name": "Barclays Live",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "520bb613ae942fa6",
      "name": "Barclays PLC",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ccf133d649c357ba",
      "name": "Barclays Research",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a99050f978a6bc4a",
      "name": "Bayer AG",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "13eec11f9f77d58d",
      "name": "Canada Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7860a2554c61a53f",
      "name": "Canadian Investment",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d704b6ac0c024d24",
      "name": "Canadian Investor",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "3d9e178724d263f9",
      "name": "Closing Price",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "599c003b7b8efa99",
      "name": "Complete Response",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4f384ac7feb02a78",
      "name": "Copyright IQVIA",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "3201bb044577cf87",
      "name": "Corporate Broker",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "95d224c524720bd7",
      "name": "Dealer Member",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "line",
        "title": null,
        "page": 3,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Week 1",
              "Week 4",
              "Week 7",
              "Week 10",
              "Week 13",
              "Week 16",
              "Week 19",
              "Week 22",
              "Week 25",
              "Week 28",
              "Week 31",
              "Week 34",
              "Week 37",
              "Week 40",
              "Week 43",
              "Week 46",
              "Week 49",
              "Week 52",
              "Week 55",
              "Week 58"
            ]
          },
          "y": {
            "unit": "TRx",
            "range": {
              "min": 0,
              "max": 8000
            }
          }
        },
        "series": [
          {
            "name": "Nemluvio (Aug 24)",
            "unit": "TRx",
            "values": [
              0,
              100,
              200,
              300,
              400,
              600,
              700,
              800,
              900,
              1100,
              1300,
              1500,
              1800,
              2000,
              2300,
              2700,
              3000,
              3500,
              3700,
              3800
            ]
          },
          {
            "name": "Ebglyss (Oct 24)",
            "unit": "TRx",
            "values": [
              0,
              50,
              100,
              150,
              200,
              250,
              300,
              400,
              500,
              700,
              900,
              1100,
              1200,
              1400,
              1600,
              1800,
              1900,
              2000,
              2000,
              2000
            ]
          },
          {
            "name": "Adbry (Feb 22)",
            "unit": "TRx",
            "values": [
              0,
              50,
              100,
              150,
              200,
              250,
              300,
              350,
              400,
              500,
              600,
              700,
              750,
              800,
              850,
              900,
              900,
              900,
              900,
              900
            ]
          },
          {
            "name": "Dupixent (Mar 17)",
            "unit": "TRx",
            "values": [
              0,
              300,
              700,
              1200,
              1700,
              2000,
              2500,
              3000,
              3500,
              4000,
              4500,
              5000,
              5500,
              5800,
              6000,
              6200,
              6500,
              6800,
              7000,
              7200
            ]
          }
        ],
        "figure_id": "490f5493e9331f4f",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 8,
        "axes": {
          "x": {
            "type": "time",
            "labels": [
              "Apr-2024",
              "Jul-2024",
              "Oct-2024",
              "Jan-2025",
              "Apr-2025",
              "Jul-2025"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 50,
              "max": 150
            }
          }
        },
        "series": [
          {
            "name": "Closing Price",
            "unit": null,
            "values": [
              {
                "x": "Apr-2024",
                "y": 60
              },
              {
                "x": "May-2024",
                "y": 70
              },
              {
                "x": "Jul-2024",
                "y": 75
              },
              {
                "x": "Aug-2024",
                "y": 70
              },
              {
                "x": "Sep-2024",
                "y": 78
              },
              {
                "x": "Oct-2024",
                "y": 75
              },
              {
                "x": "Nov-2024",
                "y": 90
              },
              {
                "x": "Dec-2024",
                "y": 105
              },
              {
                "x": "Jan-2025",
                "y": 115
              },
              {
                "x": "Feb-2025",
                "y": 110
              },
              {
                "x": "Mar-2025",
                "y": 95
              },
              {
                "x": "Apr-2025",
                "y": 75
              },
              {
                "x": "May-2025",
                "y": 90
              },
              {
                "x": "Jun-2025",
                "y": 110
              },
              {
                "x": "Jul-2025",
                "y": 125
              },
              {
                "x": "Aug-2025",
                "y": 135
              }
            ]
          },
          {
            "name": "Target Price",
            "unit": null,
            "values": [
              {
                "x": "Jul-2025",
                "y": 130
              },
              {
                "x": "Aug-2025",
                "y": 135
              }
            ]
          },
          {
            "name": "Rating Change",
            "unit": null,
            "values": [
              {
                "x": "Jul-2025",
                "y": 135
              }
            ]
          }
        ],
        "figure_id": "005c78649d5aae43",
        "provenance": {
          "page": 8
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 3,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Week 1",
              "Week 4",
              "Week 7",
              "Week 10",
              "Week 13",
              "Week 16",
              "Week 19",
              "Week 22",
              "Week 25",
              "Week 28",
              "Week 31",
              "Week 34",
              "Week 37",
              "Week 40",
              "Week 43",
              "Week 46",
              "Week 49",
              "Week 52",
              "Week 55",
              "Week 58"
            ]
          },
          "y": {
            "unit": "NRx",
            "range": {
              "min": 0,
              "max": 3000
            }
          }
        },
        "series": [
          {
            "name": "Nemluvio (Aug 24)",
            "unit": "NRx",
            "values": [
              0,
              100,
              200,
              300,
              400,
              550,
              500,
              600,
              700,
              900,
              1000,
              1100,
              1200,
              1300,
              1400,
              1200,
              1500,
              1500,
              1550,
              1600
            ]
          },
          {
            "name": "Ebglyss (Oct 24)",
            "unit": "NRx",
            "values": [
              0,
              50,
              150,
              200,
              250,
              300,
              350,
              450,
              550,
              650,
              750,
              850,
              950,
              1000,
              1100,
              1200,
              1150,
              1200,
              1250,
              1300
            ]
          },
          {
            "name": "Adbry (Feb 22)",
            "unit": "NRx",
            "values": [
              0,
              20,
              50,
              80,
              100,
              150,
              200,
              250,
              280,
              300,
              300,
              300,
              350,
              250,
              300,
              350,
              300,
              400,
              400,
              350
            ]
          },
          {
            "name": "Dupixent (Mar 17)",
            "unit": "NRx",
            "values": [
              0,
              500,
              1200,
              1100,
              1200,
              1000,
              1200,
              1400,
              1300,
              1500,
              1800,
              1800,
              1300,
              1900,
              1800,
              2400,
              2100,
              2200,
              2400,
              2600
            ]
          }
        ],
        "figure_id": "9aeece55573b035e",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 2,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "week 1",
              "week 4",
              "week 7",
              "week 10",
              "week 13",
              "week 16",
              "week 19",
              "week 22",
              "week 25",
              "week 28",
              "week 31",
              "week 34",
              "week 37",
              "week 40",
              "week 43",
              "week 46",
              "week 49",
              "week 52"
            ]
          },
          "y": {
            "unit": "TRx",
            "range": {
              "min": 0,
              "max": 3000
            }
          }
        },
        "series": [
          {
            "name": "Nemluvio (Aug 24)",
            "unit": "TRx",
            "values": [
              0,
              20,
              100,
              250,
              300,
              400,
              450,
              500,
              800,
              1000,
              1200,
              1350,
              1600,
              1800,
              1950,
              1800,
              2200,
              2800
            ]
          },
          {
            "name": "Ebglyss (Oct 04)",
            "unit": "TRx",
            "values": [
              0,
              50,
              150,
              300,
              400,
              550,
              700,
              1000,
              900,
              1200,
              1300,
              1500,
              1800,
              1500,
              2000,
              2200,
              2400,
              2700
            ]
          }
        ],
        "figure_id": "98107023cb0d80ce",
        "provenance": {
          "page": 2
        }
      },
      {
        "type": "pie",
        "title": null,
        "page": 4,
        "axes": null,
        "series": [
          {
            "name": "Doxycycline",
            "unit": null,
            "values": [
              {
                "value": 100,
                "percentage": 0.39
              }
            ]
          },
          {
            "name": "Dupixent",
            "unit": null,
            "values": [
              {
                "value": 46,
                "percentage": 0.18
              }
            ]
          },
          {
            "name": "Ebglyss",
            "unit": null,
            "values": [
              {
                "value": 16,
                "percentage": 0.06
              }
            ]
          },
          {
            "name": "Rinvoq",
            "unit": null,
            "values": [
              {
                "value": 6,
                "percentage": 0.03
              }
            ]
          },
          {
            "name": "Methotrexate",
            "unit": null,
            "values": [
              {
                "value": 8,
                "percentage": 0.03
              }
            ]
          },
          {
            "name": "Others",
            "unit": null,
            "values": [
              {
                "value": 80,
                "percentage": 0.31
              }
            ]
          }
        ],
        "figure_id": "42ea85cc216fae6c",
        "provenance": {
          "page": 4
        }
      },
      {
        "type": "pie",
        "title": null,
        "page": 4,
        "axes": {
          "x": null,
          "y": null
        },
        "series": [
          {
            "name": "Doxycycline",
            "unit": null,
            "values": [
              {
                "value": 9707,
                "percentage": 0.62
              }
            ]
          },
          {
            "name": "Nemluvio",
            "unit": null,
            "values": [
              {
                "value": 1732,
                "percentage": 0.11
              }
            ]
          },
          {
            "name": "Ebglyss",
            "unit": null,
            "values": [
              {
                "value": 1399,
                "percentage": 0.09
              }
            ]
          },
          {
            "name": "Rinvoq",
            "unit": null,
            "values": [
              {
                "value": 1221,
                "percentage": 0.08
              }
            ]
          },
          {
            "name": "Others",
            "unit": null,
            "values": [
              {
                "value": 1523,
                "percentage": 0.1
              }
            ]
          }
        ],
        "figure_id": "de24828d8c1b4b4b",
        "provenance": {
          "page": 4
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 2,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Week 1",
              "week 4",
              "week 7",
              "week 10",
              "week 13",
              "week 16",
              "week 19",
              "week 22",
              "week 25",
              "week 28",
              "week 31",
              "week 34",
              "week 37",
              "week 40",
              "week 43",
              "week 46",
              "week 49",
              "week 52"
            ]
          },
          "y": {
            "unit": "NRx",
            "range": {
              "min": 0,
              "max": 1200
            }
          }
        },
        "series": [
          {
            "name": "Nemluvio (Aug 24)",
            "unit": "NRx",
            "values": [
              0,
              20,
              100,
              210,
              180,
              240,
              180,
              280,
              350,
              450,
              520,
              600,
              780,
              700,
              900,
              780,
              980,
              1080
            ]
          },
          {
            "name": "Ebglyss (Oct 04)",
            "unit": "NRx",
            "values": [
              0,
              40,
              180,
              340,
              200,
              420,
              300,
              560,
              540,
              700,
              680,
              750,
              800,
              950,
              700,
              1050,
              950,
              1120
            ]
          }
        ],
        "figure_id": "edbc5b49f47606a8",
        "provenance": {
          "page": 2
        }
      },
      {
        "type": "pie",
        "title": null,
        "page": 4,
        "axes": null,
        "series": [
          {
            "name": "Doxycycline",
            "unit": "count",
            "values": [
              9450
            ],
            "percentage": "70%"
          },
          {
            "name": "Rinvoq",
            "unit": "count",
            "values": [
              1176
            ],
            "percentage": "9%"
          },
          {
            "name": "Ebglyss",
            "unit": "count",
            "values": [
              856
            ],
            "percentage": "6%"
          },
          {
            "name": "Nemluvio",
            "unit": "count",
            "values": [
              610
            ],
            "percentage": "4%"
          },
          {
            "name": "Others",
            "unit": "count",
            "values": [
              1459
            ],
            "percentage": "11%"
          }
        ],
        "figure_id": "8ed13ea74e2e71a7",
        "provenance": {
          "page": 4
        }
      },
      {
        "type": "pie",
        "title": null,
        "page": 4,
        "axes": null,
        "series": [
          {
            "name": "Dupixent",
            "unit": null,
            "values": [
              {
                "value": 1732,
                "percentage": 0.61
              }
            ]
          },
          {
            "name": "Doxycycline",
            "unit": null,
            "values": [
              {
                "value": 611,
                "percentage": 0.21
              }
            ]
          },
          {
            "name": "Rinvoq",
            "unit": null,
            "values": [
              {
                "value": 228,
                "percentage": 0.08
              }
            ]
          },
          {
            "name": "Ebglyss",
            "unit": null,
            "values": [
              {
                "value": 83,
                "percentage": 0.03
              }
            ]
          },
          {
            "name": "Others",
            "unit": null,
            "values": [
              {
                "value": 192,
                "percentage": 0.07
              }
            ]
          }
        ],
        "figure_id": "2155c126319a410c",
        "provenance": {
          "page": 4
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 3,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Week 1",
              "Week 3",
              "Week 5",
              "Week 7",
              "Week 9",
              "Week 11",
              "Week 13",
              "Week 15",
              "Week 17",
              "Week 19",
              "Week 21",
              "Week 23",
              "Week 25",
              "Week 27",
              "Week 29",
              "Week 31",
              "Week 33",
              "Week 35",
              "Week 37",
              "Week 39",
              "Week 41",
              "Week 43",
              "Week 45",
              "Week 47",
              "Week 49",
              "Week 51",
              "Week 53"
            ]
          },
          "y": {
            "unit": "TRx",
            "range": {
              "min": 0,
              "max": 4000
            }
          }
        },
        "series": [
          {
            "name": "Cosentyx (Feb 15)",
            "unit": "TRx",
            "values": [
              0,
              1200,
              1400,
              1800,
              2200,
              2600,
              2400,
              2700,
              2400,
              2600,
              2300,
              2700,
              2500,
              2800,
              2400,
              2700,
              2800,
              2700,
              2800,
              2900,
              2200,
              2800,
              2000,
              2800,
              2000,
              2200,
              2400
            ]
          },
          {
            "name": "Skyrizi (May 19)",
            "unit": "TRx",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "Taltz (Apr 16)",
            "unit": "TRx",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "Tremfya (Jul 17)",
            "unit": "TRx",
            "values": [
              0,
              100,
              200,
              300,
              400,
              500,
              600,
              700,
              800,
              1300,
              900,
              1000,
              1100,
              1200,
              1300,
              1400,
              1500,
              1600,
              1700,
              1800,
              1900,
              1400,
              1800,
              1900,
              1700,
              1900,
              1800
            ]
          },
          {
            "name": "Bimzelx (Nov 23)",
            "unit": "TRx",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "Nemluvio (Aug 24)",
            "unit": "TRx",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "Ebglyss (Oct 24)",
            "unit": "TRx",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          }
        ],
        "figure_id": "750b1987e13b69c2",
        "provenance": {
          "page": 3
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "4fe060c0bb10961e",
        "value": 0.001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ropean Pharmaceuticals & Life Sciences Price Target Price (28- Aug- 25) Potential Upside/Downside +0.1% Source: Bloomberg, Barclays Research",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "61d01b63904d37c0",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Galderma: Thoughts on upcoming competitor amlitelimab P3 AD data + Nemluvio Weekly Tracker: TRx up +10% WoW, NRx up +8% WoW (22/08/25)). Overall, we continue to be bullish on atopic dermatitis (AD) op",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "cff11c48274b2f06",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ts on upcoming competitor amlitelimab P3 AD data + Nemluvio Weekly Tracker: TRx up +10% WoW, NRx up +8% WoW (22/08/25)). Overall, we continue to be bullish on atopic dermatitis (AD) opportunity and se",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "36feeb5a93ce1a98",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>362</td><td>554</td><td>830</td><td>922</td><td>1097</td></tr><tr><td>Switch in / TRx (%)</td><td>25%</td><td>24%</td><td>19%</td><td>16%</td><td>11%</td><td>12%</td><td>12%</td><td>12%</td><td>14%<",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "6a45ead14e326c35",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>554</td><td>830</td><td>922</td><td>1097</td></tr><tr><td>Switch in / TRx (%)</td><td>25%</td><td>24%</td><td>19%</td><td>16%</td><td>11%</td><td>12%</td><td>12%</td><td>12%</td><td>14%</td><td>13%<",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "bb73c2152740d560",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>830</td><td>922</td><td>1097</td></tr><tr><td>Switch in / TRx (%)</td><td>25%</td><td>24%</td><td>19%</td><td>16%</td><td>11%</td><td>12%</td><td>12%</td><td>12%</td><td>14%</td><td>13%</td><td>12%<",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "f18b58122f1b8ee7",
        "value": 0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>922</td><td>1097</td></tr><tr><td>Switch in / TRx (%)</td><td>25%</td><td>24%</td><td>19%</td><td>16%</td><td>11%</td><td>12%</td><td>12%</td><td>12%</td><td>14%</td><td>13%</td><td>12%</td></tr><tr",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "fea311f13f42ce14",
        "value": 0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>1097</td></tr><tr><td>Switch in / TRx (%)</td><td>25%</td><td>24%</td><td>19%</td><td>16%</td><td>11%</td><td>12%</td><td>12%</td><td>12%</td><td>14%</td><td>13%</td><td>12%</td></tr><tr><td>Switch ",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "82bbcb363fbd5974",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/tr><tr><td>Switch in / TRx (%)</td><td>25%</td><td>24%</td><td>19%</td><td>16%</td><td>11%</td><td>12%</td><td>12%</td><td>12%</td><td>14%</td><td>13%</td><td>12%</td></tr><tr><td>Switch out</td><td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "e4de008c5b0006ea",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Switch in / TRx (%)</td><td>25%</td><td>24%</td><td>19%</td><td>16%</td><td>11%</td><td>12%</td><td>12%</td><td>12%</td><td>14%</td><td>13%</td><td>12%</td></tr><tr><td>Switch out</td><td>4</td><td>23",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "b108e8b12c2a56df",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "TRx (%)</td><td>25%</td><td>24%</td><td>19%</td><td>16%</td><td>11%</td><td>12%</td><td>12%</td><td>12%</td><td>14%</td><td>13%</td><td>12%</td></tr><tr><td>Switch out</td><td>4</td><td>23</td><td>33<",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "b6fc503ea282e3fa",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>25%</td><td>24%</td><td>19%</td><td>16%</td><td>11%</td><td>12%</td><td>12%</td><td>12%</td><td>14%</td><td>13%</td><td>12%</td></tr><tr><td>Switch out</td><td>4</td><td>23</td><td>33</td><td>89</",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "03a5fc9d70d6a431",
        "value": 0.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>24%</td><td>19%</td><td>16%</td><td>11%</td><td>12%</td><td>12%</td><td>12%</td><td>14%</td><td>13%</td><td>12%</td></tr><tr><td>Switch out</td><td>4</td><td>23</td><td>33</td><td>89</td><td>89</t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "4b81d0fbef20e27f",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>19%</td><td>16%</td><td>11%</td><td>12%</td><td>12%</td><td>12%</td><td>14%</td><td>13%</td><td>12%</td></tr><tr><td>Switch out</td><td>4</td><td>23</td><td>33</td><td>89</td><td>89</td><td>89</td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "9aa1962234a61a35",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>121</td><td>169</td><td>180</td><td>197</td><td>236</td></tr><tr><td>Switch out / TRx (%)</td><td>1%</td><td>3%</td><td>3%</td><td>5%</td><td>4%</td><td>4%</td><td>4%</td><td>4%</td><td>3%</td><td>3",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "600324a92d484379",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>169</td><td>180</td><td>197</td><td>236</td></tr><tr><td>Switch out / TRx (%)</td><td>1%</td><td>3%</td><td>3%</td><td>5%</td><td>4%</td><td>4%</td><td>4%</td><td>4%</td><td>3%</td><td>3%</td><td>3",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "15a519f783a84c88",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>180</td><td>197</td><td>236</td></tr><tr><td>Switch out / TRx (%)</td><td>1%</td><td>3%</td><td>3%</td><td>5%</td><td>4%</td><td>4%</td><td>4%</td><td>4%</td><td>3%</td><td>3%</td><td>3%</td></tr>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "4076ea9284b045d5",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>197</td><td>236</td></tr><tr><td>Switch out / TRx (%)</td><td>1%</td><td>3%</td><td>3%</td><td>5%</td><td>4%</td><td>4%</td><td>4%</td><td>4%</td><td>3%</td><td>3%</td><td>3%</td></tr><tr><td row",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "072ce2b26a8cecaf",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>236</td></tr><tr><td>Switch out / TRx (%)</td><td>1%</td><td>3%</td><td>3%</td><td>5%</td><td>4%</td><td>4%</td><td>4%</td><td>4%</td><td>3%</td><td>3%</td><td>3%</td></tr><tr><td rowspan=\"6\">EB",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "7ccd894c0109bf60",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></tr><tr><td>Switch out / TRx (%)</td><td>1%</td><td>3%</td><td>3%</td><td>5%</td><td>4%</td><td>4%</td><td>4%</td><td>4%</td><td>3%</td><td>3%</td><td>3%</td></tr><tr><td rowspan=\"6\">EBGLYSS</td><",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "6949370eaee35291",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>Switch out / TRx (%)</td><td>1%</td><td>3%</td><td>3%</td><td>5%</td><td>4%</td><td>4%</td><td>4%</td><td>4%</td><td>3%</td><td>3%</td><td>3%</td></tr><tr><td rowspan=\"6\">EBGLYSS</td><td>Switch i",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "13cbec7ec2712e86",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "out / TRx (%)</td><td>1%</td><td>3%</td><td>3%</td><td>5%</td><td>4%</td><td>4%</td><td>4%</td><td>4%</td><td>3%</td><td>3%</td><td>3%</td></tr><tr><td rowspan=\"6\">EBGLYSS</td><td>Switch in / Switch o",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "4393eec07ebd7538",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "(%)</td><td>1%</td><td>3%</td><td>3%</td><td>5%</td><td>4%</td><td>4%</td><td>4%</td><td>4%</td><td>3%</td><td>3%</td><td>3%</td></tr><tr><td rowspan=\"6\">EBGLYSS</td><td>Switch in / Switch out Ratio</",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "471fcc81daedbd6d",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">1%</td><td>3%</td><td>3%</td><td>5%</td><td>4%</td><td>4%</td><td>4%</td><td>4%</td><td>3%</td><td>3%</td><td>3%</td></tr><tr><td rowspan=\"6\">EBGLYSS</td><td>Switch in / Switch out Ratio</td><td>16.3",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "ec59b388af2c072e",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">3%</td><td>3%</td><td>5%</td><td>4%</td><td>4%</td><td>4%</td><td>4%</td><td>3%</td><td>3%</td><td>3%</td></tr><tr><td rowspan=\"6\">EBGLYSS</td><td>Switch in / Switch out Ratio</td><td>16.3</td><td>7.",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "77541d6bd97c62b5",
        "value": 0.51,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>660</td><td>640</td><td>849</td><td></td></tr><tr><td>Switch in / TRx (%)</td><td></td><td>51%</td><td>33%</td><td>24%</td><td>18%</td><td>17%</td><td>15%</td><td>12%</td><td>11%</td><td>11%<",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "c1b0538c092ba847",
        "value": 0.33,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>640</td><td>849</td><td></td></tr><tr><td>Switch in / TRx (%)</td><td></td><td>51%</td><td>33%</td><td>24%</td><td>18%</td><td>17%</td><td>15%</td><td>12%</td><td>11%</td><td>11%</td><td></td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "1c5c3b8fb1934308",
        "value": 0.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>849</td><td></td></tr><tr><td>Switch in / TRx (%)</td><td></td><td>51%</td><td>33%</td><td>24%</td><td>18%</td><td>17%</td><td>15%</td><td>12%</td><td>11%</td><td>11%</td><td></td></tr><tr><t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "7695168dada3dbeb",
        "value": 0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td></td></tr><tr><td>Switch in / TRx (%)</td><td></td><td>51%</td><td>33%</td><td>24%</td><td>18%</td><td>17%</td><td>15%</td><td>12%</td><td>11%</td><td>11%</td><td></td></tr><tr><td>Switch out",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "5e18e1997b22fcc5",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></tr><tr><td>Switch in / TRx (%)</td><td></td><td>51%</td><td>33%</td><td>24%</td><td>18%</td><td>17%</td><td>15%</td><td>12%</td><td>11%</td><td>11%</td><td></td></tr><tr><td>Switch out</td><td></t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "63c9014b2159adce",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>Switch in / TRx (%)</td><td></td><td>51%</td><td>33%</td><td>24%</td><td>18%</td><td>17%</td><td>15%</td><td>12%</td><td>11%</td><td>11%</td><td></td></tr><tr><td>Switch out</td><td></td><td></td><",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "b3bc7fcfac435732",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/ TRx (%)</td><td></td><td>51%</td><td>33%</td><td>24%</td><td>18%</td><td>17%</td><td>15%</td><td>12%</td><td>11%</td><td>11%</td><td></td></tr><tr><td>Switch out</td><td></td><td></td><td>6</td><td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "f2634a3942f6af9a",
        "value": 0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td></td><td>51%</td><td>33%</td><td>24%</td><td>18%</td><td>17%</td><td>15%</td><td>12%</td><td>11%</td><td>11%</td><td></td></tr><tr><td>Switch out</td><td></td><td></td><td>6</td><td>17</td><td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "151dc39b918b17b1",
        "value": 0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>51%</td><td>33%</td><td>24%</td><td>18%</td><td>17%</td><td>15%</td><td>12%</td><td>11%</td><td>11%</td><td></td></tr><tr><td>Switch out</td><td></td><td></td><td>6</td><td>17</td><td>22</td><td>4",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "a50ef8ab75b7237b",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "95</td><td>126</td><td>136</td><td></td></tr><tr><td>Switch out / TRx (%)</td><td></td><td></td><td>1%</td><td>1%</td><td>1%</td><td>2%</td><td>1%</td><td>2%</td><td>2%</td><td>2%</td><td></td></tr><t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "89567e8c37daae24",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "126</td><td>136</td><td></td></tr><tr><td>Switch out / TRx (%)</td><td></td><td></td><td>1%</td><td>1%</td><td>1%</td><td>2%</td><td>1%</td><td>2%</td><td>2%</td><td>2%</td><td></td></tr><tr><td>Switc",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "035f3393a3f0900f",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">136</td><td></td></tr><tr><td>Switch out / TRx (%)</td><td></td><td></td><td>1%</td><td>1%</td><td>1%</td><td>2%</td><td>1%</td><td>2%</td><td>2%</td><td>2%</td><td></td></tr><tr><td>Switch in / Swit",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "b7d5d6287d96500f",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></td></tr><tr><td>Switch out / TRx (%)</td><td></td><td></td><td>1%</td><td>1%</td><td>1%</td><td>2%</td><td>1%</td><td>2%</td><td>2%</td><td>2%</td><td></td></tr><tr><td>Switch in / Switch out Rati",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "a1f1eafd98c944ae",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>Switch out / TRx (%)</td><td></td><td></td><td>1%</td><td>1%</td><td>1%</td><td>2%</td><td>1%</td><td>2%</td><td>2%</td><td>2%</td><td></td></tr><tr><td>Switch in / Switch out Ratio</td><td><",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "e8b32efa9f7c8495",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "itch out / TRx (%)</td><td></td><td></td><td>1%</td><td>1%</td><td>1%</td><td>2%</td><td>1%</td><td>2%</td><td>2%</td><td>2%</td><td></td></tr><tr><td>Switch in / Switch out Ratio</td><td></td><td></t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "c29a4cca3e27d145",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "TRx (%)</td><td></td><td></td><td>1%</td><td>1%</td><td>1%</td><td>2%</td><td>1%</td><td>2%</td><td>2%</td><td>2%</td><td></td></tr><tr><td>Switch in / Switch out Ratio</td><td></td><td></td><td>37.8<",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "84fe6ff768931d3c",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td></td><td></td><td>1%</td><td>1%</td><td>1%</td><td>2%</td><td>1%</td><td>2%</td><td>2%</td><td>2%</td><td></td></tr><tr><td>Switch in / Switch out Ratio</td><td></td><td></td><td>37.8</td><td>23.",
        "provenance": {
          "page": 3
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 10,
      "tables_count": 0,
      "numerical_data_count": 42,
      "passages_count": 81,
      "entities_count": 20
    }
  }
}